ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 634

Characterization of CD4+ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL)

Harald Leiss1, Barbara Schwarzecker2, Irina Gessl1, Antonia Puchner1, Birgit Niederreiter2, Carl-Walter Steiner3, Josef Smolen2 and Georg H. Stummvoll4, 1Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Rheumatology, Medical University of Vienna, Vienna, Austria

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: SLE and T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

CD4+ T cells and the Th1 and Th17 subsets in particular play a pivotal role in SLE. Regulatory T cells (Treg) are essential for maintaining peripheral tolerance, but their number and function in SLE is decreased. We herein characterize CD4+T cell and Treg homeostasis and severity of organ involvement in a murine model of SLE and analyze the effects of in vitro –induced iTreg.

Methods

Mice were injected i.p. with 0.5ml of pristane or PBS as control and killed after 8 months. Na•ve CD4+ thymocytes were cultured under specific conditions and tested for CD4+Foxp3+ expression by FACS. Cell suspensions with >80% purity for CD4+FoxP3+ iTreg were injected intravenously either once at start of experiments  (iTreg-boost) or monthly  (1xiTreg-repeated).

Animals were monitored for clinical signs of arthritis and, in order to analyze and compare disease severity, histological features of arthritis and pneumonitis were quantified by an image analysis system. Lungs were scored for the severity of perivascular inflammation by analyzing the numbers of affected vessels and the area of the inflammatory infiltrate.

Lymphocytes were isolated from granulomas (intraperitoneal ectopic lymphoid tissue), lymph nodes (LN) and spleens and were analyzed separately by FACS. For analyzes of the Th1, 2 and 17 subsets, cells were restimulated in vivo plate bound with anti-CD3 and anti-CD28abs.

Results

PIL mice presented with involvement of inner organs, most frequently affected were the lungs (100% pneumonitis); 52% of PIL developed arthritis, both clinically and histologically. Monthly iTreg-injection significantly decreased clinical signs of arthritis and histological lung and joint parameters. 66% of treated mice did not show any signs of arthritis at all. (Fig. 1A-F)

The iTreg-boost did not prevent joint manifestations or pneumonitis, but appeared to have a retarding effect (Fig.1A-F) indicated by a delayed onset of clinical symptoms and by a significantly decreased erosive area at the end of observation (Fig.1B).

Intraperitoneal granuloma typical for PIL appeared to be the hotspots of inflammation showing a significantly elevated Teff/Treg ratio of 1.3. Upon re-stimulation, CD4+ cells showed a pronounced Th1 response (27% IFNγ producers) compared to cells from LN and spleens from both PIL and HC (with Th1 percentages ranging from 9-16%). In addition, frequencies of Th2 and Th17 cells were elevated in PIL, again with the highest yield in granuloma. The repeated application of iTreg reduced the Teff/Treg ratio in PIL granuloma to 0.7.

Conclusion

Repeated injections of iTregs reduce severity of pneumonitis and arthritis as well as the Teff/Treg ratio. A single injection of iTregs is not effective, but appears to retard onset of symptoms and progression of arthritis and pneumonitis. Thus, iTreg have significant effects on lupus symptoms, which may have consequence for future therapeutic considerations.

Beschreibung: Macintosh HD:Users:Dino:Dropbox:Labor:Output:Abstracts:2014:Harald Leiss Treg Figure1.jpg


Disclosure:

H. Leiss,
None;

B. Schwarzecker,
None;

I. Gessl,
None;

A. Puchner,
None;

B. Niederreiter,
None;

C. W. Steiner,
None;

J. Smolen,
None;

G. H. Stummvoll,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-cd4-t-cell-response-and-effects-of-regulatory-t-cells-in-pristane-induced-lupus-pil/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology